Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

Pfizer, Merck to jointly develop and commercialize new cancer treatments Pfizer has entered into an agreement with Merck to jointly develop and commercialize MSB0010718C, an investigational anti-PD-L1 antibody being developed by Merck as a potential treatment for several types of cancer. Contract Research & Services > Contract Services > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

Otologic starts Phase I HNPN-1010 trial to treat hearing disorders
By PBR Staff Writer
Otologic Pharmaceutics (OPI) has initiated a Phase I clinical trial of its lead product candidate HNPN-1010 to treat acute sensorineural hearing loss.
News
Galena Biopharma closes enrollment in Phase II trial of GALE-401
By PBR Staff Writer
US-based Galena Biopharma has completed patient enrollment in the GALE-401, or Anagrelide Controlled Release, Phase II clinical trial to treat patients with elevated platelet counts in myeloproliferative neoplasms (MPNs).
News

Contract Research

OnCore, Blumberg enter exclusive HBV research collaboration
By PBR Staff Writer
US-based OnCore Biopharma has entered into a hepatitis B virus (HBV) and liver cancer research collaboration with the Baruch S. Blumberg Institute (Blumberg), the research center of the Hepatitis B Foundation.
News
CDISC and TransCelerate announce availability of new standards for diabetes and cardiovascular disease
The Clinical Data Interchange Standards Consortium and TransCelerate BioPharma are pleased to announce the availability of therapeutic area (TA) standards for diabetes and cardiovascular (CV) disease areas through the Coalition for Accelerating Standards and Therapies (CFAST), a joint initiative of CDISC and the Critical Path Institute (C-Path).
News

Contract Services

Apellis Pharmaceuticals to acquire Potentia Pharmaceuticals
Apellis Pharmaceuticals announced that it entered into an agreement to acquire Potentia Pharmaceuticals.
News
3SBio enters into license deal with PharmAbcine for Tanibirumab
By PBR Staff Writer
Chinese biotechnology firm 3SBio has entered into an exclusive license with PharmAbcine to develop, manufacture and market Tanibirumab, an anti-VEGFR2/KDR antibody for cancer.
News